Reiffers J, Goldman J, Meloni G, Cahn J Y, Faberes C, Apperley J
Bone Marrow Transplant Unit, CHRBordeaux Hôpital, Pessac, France.
Bone Marrow Transplant. 1994;14 Suppl 3:S51-4.
Autologous stem cell transplantation (ASCT) was performed in 95 patients with chronic myelogenous leukemia (CML) in chronic phase and their data were reported to the European Bone Marrow Transplant Registry. Most patients presented bad prognostic factors. The results were analysed by September 1, 1993. The actuarial proportion of patients who achieved a complete hematological response at one year was 87.3+/-7.5% (95% CI). The 3-year percentage of major cytogenetic response was 38.6+/--13% (95% CI). The actuarial risk of transformation for the evaluable patients was 31.5+/-14% (95% CI) and the actuarial survival at four years was 83.3+/-10% (95% CI). These encouraging results suggest that ASCT by itself could play a role to prolong survival in CML patients.
95例慢性期慢性粒细胞白血病（CML）患者接受了自体干细胞移植（ASCT），其数据已上报至欧洲骨髓移植登记处。大多数患者存在不良预后因素。截至1993年9月1日对结果进行了分析。1年时达到完全血液学缓解的患者的精算比例为87.3±7.5%（95%置信区间）。主要细胞遗传学缓解的3年百分比为38.6±13%（95%置信区间）。可评估患者的精算转化风险为31.5±14%（95%置信区间），4年时的精算生存率为83.3±10%（95%置信区间）。这些令人鼓舞的结果表明，自体干细胞移植本身可能在延长CML患者生存期方面发挥作用。
